{"version":"1.0","type":"link","title":"Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma.","author_name":"Chiang ST 외","author_url":"https://prs-insight.online/author/Chiang%20ST","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/168976","thumbnail_width":1200,"thumbnail_height":630}